Category: Wall Street Beat
GI Dynamics shareholders are slated to vote on whether to approve a 1-for-10 reverse stock split in an effort to raise the company's lagging share price.
Allergan says there's no evidence to back claims by hostile suitors Valeant Pharmaceuticals and hedge mogul William Ackman's Pershing Square Capital Management that Allergan CEO David Pyott led a smear campaign against them.
Breast implant maker Sientra raised the upper limit on its planned initial public offering of stock to $92 million, after filing in mid-September for an $86 million IPO.
Breast implant maker Sientra set a price range for its planned initial public offering and raised the upper limit to $92 million, after filing in mid-September for an $86 million IPO.
John Flannery's experience in global markets landed him the top spot at GE Healthcare, where he replaced John Dineen, GE CEO Jeffrey Immelt told analysts last week.
Five major factors will determine the future of the medical device industry, according to a report from consulting firm A.T. Kearney.
Five disruptive factors playing out for the medical device industry will shape its course going forward, according to a report from consulting firm A.T. Kearney.
The report was culled from interviews with more than 30 executives from 20 companies spanning the medical device space, according to a press release.
Venture capital investment in medical device companies rose both in terms of value and volume during the 3rd quarter, according to the MoneyTree report from PricewaterhouseCoopers and the National Venture Capital Assn., based on Thomson Reuters data.
Venture capital shops got behind medtech during the 3rd quarter, increasing their spend and the number of deals compared with the same period last year, according to the MoneyTree report from PricewaterhouseCoopers and the National Venture Capital Assn., based on Thomson Reuters data.
Investors eye 3rd-quarter data for evidence that Obamacare is driving an increase in procedure volumes.
(Reuters) – Hospitals and insurers are expected to give their clearest view yet on whether people are having more surgeries and other medical procedures during the next few weeks when they report earnings, according to investors who are closely watching U.S. medical services use.